The effect of IL-17 and IL-23 ınhibitors on hematological ınflammatory parameters in patients with psoriasis vulgaris.

IF 1.7 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Irish Journal of Medical Science Pub Date : 2025-06-02 DOI:10.1007/s11845-025-03969-6

Mehmet Semih Çelik, Hamza Aktaş

{"title":"The effect of IL-17 and IL-23 ınhibitors on hematological ınflammatory parameters in patients with psoriasis vulgaris.","authors":"Mehmet Semih Çelik, Hamza Aktaş","doi":"10.1007/s11845-025-03969-6","DOIUrl":null,"url":null,"abstract":"Background and objective: IL-17 and IL-23 inhibitors are widely used as biological agents in patients with psoriasis vulgaris to suppress inflammation and reduce disease severity. This study aimed to examine changes in inflammatory parameters, including neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), systemic inflammation index (SII), platelet/hemoglobin ratio (PHR), and red cell distribution width/platelet ratio (RPR), as well as the Psoriasis Area and Severity Index (PASI), in psoriasis patients receiving biological therapy (IL-17 and IL-23 inhibitors).Materials and methods: This retrospective study included 110 patients with psoriasis vulgaris treated with IL-23 (risankizumab, guselkumab or IL-17 inhibitors ( secukinumab, and ixekizumab). Disease severity was assessed using the PASI score. Hematological parameters (NLR, PLR, SII, PHR, and RPR) and PASI values of the patients were recorded and analyzed at baseline (month 0) and during treatment (month 6).Results: A significant decrease was observed in NLR, SII, and PHR values during treatment. NLR decreased significantly from 2.43 ± 1.25 at baseline to 2.12 ± 0.81 at month 6 (p = 0.002). Both IL-17 and IL-23 groups significantly reduced NLR (p = 0.044, p = 0.029, respectively). SII decreased significantly from 695 ± 390 at baseline to 588 ± 288 at month 6 (p = 0.002). Both groups significantly reduced SII levels (p = 0.044, p = 0.018, respectively).PHR decreased significantly from 19.8 ± 6.60 at baseline to 19.2 ± 6.58 at month 6 (p = 0.033).PASI score significantly decreased during treatment (p < 0.001).Conclusion: The significant reduction in NLR and SII levels in both the IL-17 and IL-23 groups suggests that these markers may be used together rather than separately in treatment follow-up. The significant decrease in PHR levels may indicate that IL-17 and IL-23 inhibitors contribute to reducing cardiovascular disease risk in patients with psoriasis vulgaris and promote a favorable long-term prognosis.","PeriodicalId":14507,"journal":{"name":"Irish Journal of Medical Science","volume":" ","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Irish Journal of Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11845-025-03969-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objective: IL-17 and IL-23 inhibitors are widely used as biological agents in patients with psoriasis vulgaris to suppress inflammation and reduce disease severity. This study aimed to examine changes in inflammatory parameters, including neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), systemic inflammation index (SII), platelet/hemoglobin ratio (PHR), and red cell distribution width/platelet ratio (RPR), as well as the Psoriasis Area and Severity Index (PASI), in psoriasis patients receiving biological therapy (IL-17 and IL-23 inhibitors).

Materials and methods: This retrospective study included 110 patients with psoriasis vulgaris treated with IL-23 (risankizumab, guselkumab or IL-17 inhibitors ( secukinumab, and ixekizumab). Disease severity was assessed using the PASI score. Hematological parameters (NLR, PLR, SII, PHR, and RPR) and PASI values of the patients were recorded and analyzed at baseline (month 0) and during treatment (month 6).

Results: A significant decrease was observed in NLR, SII, and PHR values during treatment. NLR decreased significantly from 2.43 ± 1.25 at baseline to 2.12 ± 0.81 at month 6 (p = 0.002). Both IL-17 and IL-23 groups significantly reduced NLR (p = 0.044, p = 0.029, respectively). SII decreased significantly from 695 ± 390 at baseline to 588 ± 288 at month 6 (p = 0.002). Both groups significantly reduced SII levels (p = 0.044, p = 0.018, respectively).PHR decreased significantly from 19.8 ± 6.60 at baseline to 19.2 ± 6.58 at month 6 (p = 0.033).PASI score significantly decreased during treatment (p < 0.001).

Conclusion: The significant reduction in NLR and SII levels in both the IL-17 and IL-23 groups suggests that these markers may be used together rather than separately in treatment follow-up. The significant decrease in PHR levels may indicate that IL-17 and IL-23 inhibitors contribute to reducing cardiovascular disease risk in patients with psoriasis vulgaris and promote a favorable long-term prognosis.

查看原文本刊更多论文

IL-17和IL-23 ınhibitors对寻常型银屑病患者血液学ınflammatory参数的影响。

背景与目的：IL-17和IL-23抑制剂作为生物制剂广泛应用于寻常型银屑病患者，具有抑制炎症、降低病情严重程度的作用。本研究旨在探讨接受生物治疗（IL-17和IL-23抑制剂）的银屑病患者炎症参数的变化，包括中性粒细胞/淋巴细胞比（NLR）、血小板/淋巴细胞比（PLR）、全身炎症指数（SII）、血小板/血红蛋白比（PHR）、红细胞分布宽度/血小板比（RPR）以及银屑病面积和严重程度指数（PASI）。材料和方法：本回顾性研究纳入了110例接受IL-23(瑞尚单抗、guselkumab或IL-17抑制剂（secukinumab和ixekizumab）治疗的寻常型银屑病患者。使用PASI评分评估疾病严重程度。记录并分析患者在基线（第0个月）和治疗期间（第6个月）的血液学参数（NLR、PLR、SII、PHR和RPR）和PASI值。结果：治疗期间NLR、SII、PHR值均显著降低。NLR从基线时的2.43±1.25下降到第6个月时的2.12±0.81 （p = 0.002）。IL-17和IL-23组均显著降低NLR （p = 0.044, p = 0.029）。SII由基线时的695±390降至第6个月时的588±288 （p = 0.002）。两组患者SII水平均显著降低（p = 0.044, p = 0.018）。PHR从基线时的19.8±6.60降至第6个月时的19.2±6.58 （p = 0.033）。结论：IL-17组和IL-23组患者NLR和SII水平均显著降低，提示在治疗随访中可联合使用这两种标志物，而非单独使用。PHR水平的显著下降可能表明IL-17和IL-23抑制剂有助于降低寻常型银屑病患者的心血管疾病风险，并促进良好的长期预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Irish Journal of Medical Science 医学-医学：内科

CiteScore

3.70

自引率

4.80%

发文量

357

审稿时长

4-8 weeks

期刊介绍： The Irish Journal of Medical Science is the official organ of the Royal Academy of Medicine in Ireland. Established in 1832, this quarterly journal is a contribution to medical science and an ideal forum for the younger medical/scientific professional to enter world literature and an ideal launching platform now, as in the past, for many a young research worker. The primary role of both the Academy and IJMS is that of providing a forum for the exchange of scientific information and to promote academic discussion, so essential to scientific progress.